Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Rating Reaffir

B. Riley reissued their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a report issued on Thursday morning, Benzinga reports. The brokerage currently has a $55.00 price target on the biotechnology company’s stock. B. Riley also issued estimates for Arrowhead Pharmaceuticals’ FY2025 earnings at ($3.13) EPS. A number of other equities […]

Related Keywords

United States , China , Piper Sandler , Christopher Richard Anzalone , Arrowhead Pharmaceuticals , Arrowhead Pharmaceuticals Inc , News Ratings For Arrowhead Pharmaceuticals Daily , Analyst Recommendations For Arrowhead Pharmaceuticals , Advisors Asset Management Inc , Arrowhead Pharmaceuticals Price Performance , Securities Exchange Commission , Sumitomo Mitsui Financial Group , China Universal Asset Management Co , Belpointe Asset Management , Quadrant Capital Group , Arrowhead Pharmaceuticals Company Profile , Free Report , Arrowhead Pharmaceutical , Mitsui Financial Group , Moderate Buy , Get Free Report , Richard Anzalone , Director Douglas , Exchange Commission , Asset Management , Universal Asset Management , Capital Group , Captrust Financial Advisors , Financial Advisors , Arrowhead Pharmaceuticals Daily , Nasdaq Arwr , Arwr , Medical , Reiterated Rating , B Riley ,